Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Center LaboratoriesROCO:4123 +1.35%69 EBITDA Margin % is 2,157.38% as of Dec. 2025, which is 12027% above its 10-year median of 17.79. GuruFocus rates ROCO:4123 with a GF Score™ of 69/100 and a GF Value™ of NT$43.04 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Center Laboratories ranks better than 99.69% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Center Laboratories's EBITDA for the
three
months ended in Dec. 2025 was NT$8,619 Mil. Center Laboratories's Revenue for the
three
months ended in Dec. 2025 was NT$400 Mil. Therefore, Center Laboratories's EBITDA margin for the quarter that ended in Dec. 2025 was 2,157.38%.
Center Laboratories (ROCO:4123) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Center Laboratories EBITDA Margin % Related Terms
Center Laboratories EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Center Laboratories's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4123 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Center Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Center Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Center Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Center Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Center Laboratories (ROCO:4123) has a EBITDA Margin % of 2,157.38% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Center Laboratories and its competitors. This is 12027% above median its historical median of 17.79. According to the industry distribution chart, Center Laboratories ranks #3 out of 959 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Center Laboratories' EBITDA Margin % too high?
Center Laboratories' current EBITDA Margin % of 2,157.38% is 12027% above median its 10-year median of 17.79. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Center Laboratories' value of 2,157.38% is 17104% above this industry median. Based on the distribution chart, Center Laboratories ranks #3 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Center Laboratories has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Center Laboratories' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Center Laboratories ranks #3 out of 959 companies for EBITDA Margin %. This places Center Laboratories in the top 0% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.54. Center Laboratories' value of 2,157.38% is 17104% above this benchmark. While the company's 10-year median is 17.79 vs. the industry median of 12.54, Center Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Center Laboratories's current EBITDA Margin % of 2,157.38% is 17104% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Center Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Center Laboratories's current EBITDA Margin % is 2,157.38%, which is 12027% above median its own 10-year median of 17.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Center Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Center Laboratories (ROCO:4123) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$43.04, compared to a current price of NT$37.50 — trading 12.9% below its estimated fair value. The current EBITDA Margin % is 2,157.38%, which is 12027% above median its 10-year median of 17.79 and 17104% above the Drug Manufacturers industry median of 12.54. Center Laboratories' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Center Laboratories (ROCO:4123), the current EBITDA Margin % is 2,157.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Center Laboratories (ROCO:4123) Overvalued in 2026?
Based on GuruFocus' analysis, Center Laboratories stock appears to be undervalued.
The current stock price of NT$37.50 is trading 12.9% below its estimated GF Value™ of NT$43.04.
GuruFocus considers Center Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4123:
EBITDA Margin %: 2,157.38% (12027% above median its 10-year median of 17.79)
GF Value™: NT$43.04 vs. price of NT$37.50 (12.9% below fair value)
Industry Position: 17104% above the Drug Manufacturers median (#3 of 959)
No single metric tells the full story. See the ROCO:4123 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Center Laboratories Inc is engaged in the manufacture and sale of various Western pharmaceuticals, including Western medicine manufacturing, wholesale, and retail. The Company operates through the following segments: Pharmaceutical Division, Biotechnology Venture Capital, and Glac Segment. The Pharmaceutical Division, which generates the majority of revenue, manufactures and sells various Western pharmaceuticals. The Biotechnology Venture Capital segment invests in domestic and foreign biotechnology undertakings, while the Glac Segment manufactures and sells probiotic products. The Company operates in Taiwan, Mainland China, and other regions, with Taiwan generating the majority of revenue.
69GF Score
Get the complete analysis for ROCO:4123
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4123 has been successfully added to your 
